Cancer Family
Meningothelial Cell Neoplasm
CI-CAN-00000263Explore in graph →
Non-malignant65 active trials2 evidence items
- NCIt
- C6971
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000263Explore in graph →
Clinical trials
185 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06014905 | Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma | recruiting | Phase 1 | 50 | Charlie Wang, MD, PhDOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07150806 | RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma | recruiting | Phase 1 / Phase 2 | 30 | Joshua PalmerOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07652762 |
| IN10018 in Combination With Dalpiciclib for Progressive Meningiomas |
| recruiting |
| Phase 1 |
| 24 |
| Capital Medical UniversityOTHER |
| 1 |
| Aug 7, 2026 |
| clinicaltrials |
| NCT03604978 | Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma | active not recruiting | Phase 1 / Phase 2 | 38 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05278208 | Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors | recruiting | Phase 1 / Phase 2 | 65 | Nationwide Children's HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07708285 | Luvometinib in Combination With Serplulimab for NF2-Related Tumors | not yet recruiting | Phase 1 / Phase 2 | 30 | Beijing Tiantan HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06607692 | Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).(LUPARPED) | recruiting | Phase 1 / Phase 2 | 25 | Fundación de investigación HMOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05636618 | Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors | recruiting | Phase 1 / Phase 2 | 300 | Perspective TherapeuticsINDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT06650163 | Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors | recruiting | Phase 1 | 20 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT04541082 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | recruiting | Phase 1 | 102 | Jazz PharmaceuticalsINDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT04997317 | Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide(PROMENADE) | recruiting | Phase 1 / Phase 2 | 18 | University Hospital, Basel, SwitzerlandOTHER | 1 | Apr 13, 2025 | clinicaltrials |
| NCT06640582 | TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas(BAH2472) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Nov 5, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Aug 14, 2026source: clinicaltrials